Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q14626
UPID:
I11RA_HUMAN
Alternative names:
-
Alternative UPACC:
Q14626; Q16542; Q5VZ80; Q7KYJ7
Background:
Interleukin-11 receptor subunit alpha (IL11RA) plays a pivotal role in the IL11 signaling pathway, essential for craniofacial bones and teeth development. It functions as a receptor for IL11, facilitating signal transmission through IL6ST for cell proliferation and differentiation, particularly in mesenchymal cells. The soluble form, sIL11RA, enhances IL11 activity, enabling signaling in cells lacking membrane-bound IL11RA.
Therapeutic significance:
IL11RA's involvement in craniosynostosis and dental anomalies highlights its therapeutic potential. Understanding the role of Interleukin-11 receptor subunit alpha could open doors to potential therapeutic strategies for treating craniofacial developmental disorders.